License and Collaboration Agreements - Narrative (Detail)	1 Months Ended			3 Months Ended
	Oct. 31, 2018 USD ($)	Apr. 30, 2017 USD ($)	Feb. 28, 1997 shares	Mar. 31, 2022 USD ($) Obligation promise	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 16, 2021 USD ($)	Dec. 31, 2019 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Material promises | promise				6
Milestone payment recognized as revenue				$ 24,861,000	$ 16,427,000
Other Current Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Short-term liability				$ 400,000		$ 400,000
Almirall
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of performance obligations | Obligation				2
Milestone payment recognized as revenue				$ 500,000	600,000
Tufts
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Shares issued in connection with license agreement shares | shares			1,024
Milestone payments maximum amount				300,000
First milestone payment following phase 3 clinical trail for omadacycline				50,000
Second milestone payment amount following marketing application submission				100,000
Final milestone payment FDA approval of omadacycline	$ 150,000
Minimum royalty payment per year				25,000
Royalty expense				$ 300,000	$ 200,000
Maximum | Tufts
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicensing fees (in percent)				14.00%
Minimum | Tufts
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicensing fees (in percent)				10.00%
Zai Lab (Shanghai) Co., Ltd.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of performance obligations | Obligation				2
Revenue recognition milestone revenue				$ 21,500,000
Milestone payment recognized as revenue				6,000,000
Deferred revenue				0		0
Zai Lab (Shanghai) Co., Ltd. | Paratek Bermuda Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront cash payment		$ 7,500,000
Upfront cash payment due upon new drug applications acceptance	$ 5,000,000
Upfront cash payment due upon submission of first regulatory approval application for a licensed product								$ 3,000,000
Upfront cash payment due upon regulatory approval for a licensed product							$ 6,000,000
Zai Lab (Shanghai) Co., Ltd. | Paratek Bermuda Ltd | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential future commercial milestone payment				$ 40,500,000
Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Advance notice to terminate collaboration agreement				60 days
Percentage of royalty on net sales				0.25%
Patent licensing arrangement paid support period				10 years
Novartis | Other Long Term Liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Long-term liability				$ 2,700,000		$ 2,800,000